Sam is CEO of Quench Bio and an Entrepreneur-in-Residence at Atlas Venture. She brings nearly 25 years of experience in life sciences to the role. Previously, Sam was CBO of Padlock Therapeutics until its sale to BMS and COO for Synlogic. Sam is also on the board of Hotspot Therapeutics and has been an advisor to several Atlas portfolio companies. In prior roles, Sam served as vice president of Biogen corporate development, leading M&A and licensing transactions and serving as program executive for preclinical and launch-stage products. Prior to Biogen Idec, Sam led licensing and M&A transactions across multiple business units of Genzyme. Sam earned a BA and BE in biology and biomedical engineering at Dartmouth and earned an MBA from the Tuck School. Beyond biotech, Sam serves on the board of Thayer School of Engineering at Dartmouth and loves hiking, snow skiing and waterskiing.